Cargando…
Successful use of mepolizumab for severe hypereosinophilic vasculitis with c-ANCA positivity in a previously healthy 7-year-old boy
An unusual case of a pediatric patient with severe eosinophilic vasculitis causing digital ischemia is reported. The patient responded well to the anti–IL-5 agent mepolizumab, lending support for use of mepolizumab in pediatric patients with hypereosinophilic syndromes.
Autores principales: | Fox, Eryn, Cohen, Barrie, Treyster, Zoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509853/ https://www.ncbi.nlm.nih.gov/pubmed/37780105 http://dx.doi.org/10.1016/j.jacig.2022.09.009 |
Ejemplares similares
-
Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
por: Kay, Dana, et al.
Publicado: (2018) -
Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis
por: Alves, José Mario, et al.
Publicado: (2021) -
Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome
por: Pane, Fabrizio, et al.
Publicado: (2022) -
Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Fujii, Koki, et al.
Publicado: (2020) -
Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome
por: Roufosse, Florence, et al.
Publicado: (2023)